Skip to main content
OpenTrials
Completed

NCT Number: NCT04429490

Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region. National incidence has doubled for men and tripled for women between 1982 and 2012. Pancreatic adenocarcinoma is the deadliest digestive cancer, with only 7 to 8% all stages 5-year survival. It will become the second deadliest in Europe, behind bronchopulmonary cancer.

Several risk factors have been identified such as diabetes, tobacco, chronic pancreatitis or obesity. However, a mismatch exists between incidence forecasts and actual risk factors knowledge. Several hypothesis plead for an environnemental cause.

Plant protection products oncogenetic effects are known and have been proved to be responsible for tumors, including haematological malignancies. Its role in pancreatic carcinogenesis is still poorly studied and show heterogeneous results. They do not allow to conclude for causality. Organochlorines is a specific subset of plant protection product that store in lipids during lifetime.

The aim is to study association between organochlorine concentration in adipose tissue with pancreatic adenocarcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Pancreatic Ductal

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Damien JOLLY

Reims, France

About this study

Unicentric prospective case control study comparing organochlorine levels including patients diagnosed with a pancreatic adenocarcinoma undergoing a surgery allowing to collect an adipose tissue sample (10g).

Controls are adults with no pancreatic cancer (excluded by a 6 months old computed tomography excluding the probability of a pancreatic neoplasm), paired with cases upon age and body mass index, with a scheduled surgical procedure allowing to collect an adipose tissue sample without extending procedure length.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Cases :

  • patients diagnosed with a pancreatic adenocarcinoma, all stages allowed
  • undergoing a surgery allowing to take a 10 grams adipose tissue sample

Controls :

  • patients without a pancreatic neoplasm on a 6 months old CT scan before inclusion
  • undergoing a surgery allowing to take a 10 grams adipose tissue sample

Exclusion criteria

Cases :

  • patients diagnosed with a pancreatic adenocarcinoma developed on IPMN or cystadenoma
  • patient with a known genetic predisposition increasing pancreatic adenocarcinoma risk
  • histopathology proof of a mixed neuroendocrine neoplasm
  • no surgery allowing to take a 10 grams adipose tissue sample

Controls :

  • patients with a pancreatic neoplasm on a 6 months old CT scan before inclusion
  • no surgery allowing to take a 10 grams adipose tissue sample

Treatment and study plan

Adipose tissue sampling during surgery and urine sampling

Other

Adipose tissue sampling during surgery and urine sampling

Primary outcomes

  1. Adipose tissue organochlorine concentration

    Time frame: Day 0

    QuEChERS method to extract organochlorines Use of Agilent 7010 Detection limit : 10ng/g of adipose tissue

Secondary outcomes

  1. Urine organochlorine concentration

    Time frame: Day 0

    Use of Agilent 7010 Detection limit : 0.1microg/L

Sponsors and collaborators

Lead sponsor

CHU de Reims

Other

Registry information

Official study title

Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma : a Case Control Study.

Acronym: PESTIPAC

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Jun 12, 2020
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.